Dergiler / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 5

The impact of cytochrome P 450 2 C19 polymorphism on the occurrence of 1-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study

Sayfa
354–354
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

KRACSKÓ, B. (2015). The impact of cytochrome P 450 2 C19 polymorphism on the occurrence of 1-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 5, 354–354. https://ajindex.com/articles/365887

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Nozari Y, Vosooghi S, Boroumand M, Poorhosseini H, Nematipour E, Salarifar M, et al. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study. Anatol J Cardiol 2015; 15: 348-53
  2. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 2010; 56: 134-43. [CrossRef] 3. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75. [CrossRef] 4. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7. [CrossRef] 5. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62. [CrossRef] 6. Lin YJ, Li JW, Zhang MJ, Qian L, Yang WJ, Zhang CL, et al. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment. CNS Neurosci Ther 2014; 20: 125-30. [CrossRef] 7. Guo B, Tan Q, Guo D, Shi Z, Zhang C, Guo W. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg 2014; 60: 993-1001. [CrossRef] 8. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588. [CrossRef]